Eli Lilly announced the results of the Phase 3 ACHIEVE-4 study, showing that Foundayo reached the main end point compared to insulin glargine in adult type 2 diabetics: it was not inferior to cardiovascular risk. Main results: 1. Compared with insulin glargine, FoundAyo reduced the risk of MACE-4 by 16%, meeting the criteria for non-poor efficacy. 2. Pre-set analyses showed that the risk of cardiovascular death was reduced by 53%, and the risk of all-cause death was reduced by 57%. 3. At 52 weeks of treatment, Foundayo reduced glycated hemoglobin by 1.6% and body weight by 8.8%, while the glycine insulin group increased body weight by 1.7%. 4. The most common adverse events were nausea, vomiting, and diarrhea; 10.6% of Foundayo patients stopped taking medication due to adverse events. 5. Eli Lilly is currently conducting ATTAIN-DEFECTION, a Foundayo Phase 3 study on adult patients with confirmed cardiovascular or renal disease.

Eli Lilly announced the results of the Phase 3 ACHIEVE-4 study, showing that Foundayo reached the main end point compared to insulin glargine in adult type 2 diabetics: it was not inferior to cardiovascular risk. Main results: 1. Compared with insulin glargine, FoundAyo reduced the risk of MACE-4 by 16%, meeting the criteria for non-poor efficacy. 2. Pre-set analyses showed that the risk of cardiovascular death was reduced by 53%, and the risk of all-cause death was reduced by 57%. 3. At 52 weeks of treatment, Foundayo reduced glycated hemoglobin by 1.6% and body weight by 8.8%, while the glycine insulin group increased body weight by 1.7%. 4. The most common adverse events were nausea, vomiting, and diarrhea; 10.6% of Foundayo patients stopped taking medication due to adverse events. 5. Eli Lilly is currently conducting ATTAIN-DEFECTION, a Foundayo Phase 3 study on adult patients with confirmed cardiovascular or renal disease.